Clinical Trials
31 trialsAn Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy
M.D. Anderson Cancer Center
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
REPOTHYROID-II
Radboud University Medical Center
Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
Memorial Sloan Kettering Cancer Center
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
177Lu-CTR-FAPI for the Treatment of Thyroid Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
NEO-COMBATXL
UNC Lineberger Comprehensive Cancer Center
Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma
Memorial Sloan Kettering Cancer Center
Prospective Comparison of the Effect on Antiadhesive Barriers During Thyroid Surgery
National Taiwan University Hospital
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
Memorial Sloan Kettering Cancer Center
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
CNSI-Fe(II)
Sichuan Enray Pharmaceutical Sciences Company
Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
Thomas Jefferson University
Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer
Osaka University
Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer
The First Affiliated Hospital of Xiamen University
TARGET-beva
University Medical Center Groningen
Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
Roswell Park Cancer Institute
To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
Zhujiang Hospital
Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123
University of Colorado, Denver
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer
AHS Cancer Control Alberta
Spectroscopy With Surface Coils and Decoupling
Memorial Sloan Kettering Cancer Center
Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
University of Washington
Rapamycin With Grapefruit Juice for Advanced Malignancies
University of Chicago
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
Rutgers, The State University of New Jersey
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
Case Comprehensive Cancer Center